Jennifer Zachary Joins REGENXBIO Board of Directors

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) appointed Jennifer Zachary to its Board of Directors effective June 3, 2022. With over 20 years of experience in the pharmaceutical and medical device industries, she will also serve on the Audit Committee. Zachary, currently the Executive Vice President and General Counsel of Merck, brings significant legal and regulatory expertise. Her addition is seen as pivotal for REGENXBIO as it implements its '5x'25' strategy aimed at advancing five AAV Therapeutics to pivotal or commercial stages by 2025.

Positive

• Jennifer Zachary's extensive experience in legal and regulatory matters enhances the Board's expertise.
• Her appointment aligns with REGENXBIO's strategy to advance its pipeline of AAV Therapeutics.

Negative

• None.

ROCKVILLE, Md., June 7, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Jennifer Zachary to its Board of Directors, effective June 3, 2022. Ms. Zachary will serve as a member of REGENXBIO's Audit Committee and brings 20 years of legal and regulatory experience working in the pharmaceutical and medical device industries.

"We are pleased to welcome Jennifer to our Board of Directors," said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO. "Jennifer is an accomplished pharmaceutical executive with a wealth of knowledge and experience. I am certain she will be a great addition to our Board and we look forward to her contributions as we execute against our '5x'25' strategy and grow our pipeline of AAV Therapeutics."

"I am honored to join the REGENXBIO Board of Directors. This is an exciting time for the company as it executes on its strategy, grows its pipeline, and seeks to improve lives," said Ms. Zachary. "REGENXBIO is a leader in the development of gene therapies across a broad range of diseases. I look forward to collaborating with the Board and the company's management team to support bringing these critical gene therapies to patients."

Ms. Zachary is the Executive Vice President and General Counsel of Merck. In this role, she serves as a legal advisor to Merck's directors and executives, leads the company's office of general counsel and sets the company's global legal strategy. She is also responsible for the company's global safety and environment, and global security functions. Prior to joining Merck, Ms. Zachary was a partner and associate at the international law firm Covington & Burling, LLP. She practiced in the area of pharmaceutical and medical device regulatory law and advised a wide range of manufacturers and trade associations on compliance with government requirements for the development, manufacture and sale of their products. Prior to that, Ms. Zachary served as an Associate Chief Counsel for enforcement at the U.S. Food and Drug Administration and as a Special Assistant U.S. Attorney in the Civil Division of the U.S. Attorney's Office for the District of Columbia.

Ms. Zachary holds a B.S./B.A. in biology and chemistry from Arizona State University and a J.D. from Harvard Law School.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.

Contacts:

Dana Cormack 
Corporate Communications 
dcormack@regenxbio.com

Investors:

Chris Brinzey, ICR Westwicke 
339-970-2843 
Chris.brinzey@westwicke.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/jennifer-zachary-joins-regenxbio-board-of-directors-301562460.html

SOURCE REGENXBIO Inc.

FAQ

Who is Jennifer Zachary and what role does she play at REGENXBIO?

Jennifer Zachary is appointed to the Board of Directors of REGENXBIO and will also serve on its Audit Committee, effective June 3, 2022.

What experience does Jennifer Zachary bring to REGENXBIO?

She brings over 20 years of experience in the pharmaceutical and medical device industries, including her current role as Executive Vice President and General Counsel at Merck.

What is REGENXBIO's '5x'25' strategy?

The '5x'25' strategy aims to advance five AAV Therapeutics into pivotal-stage or commercial products by 2025.

How might Jennifer Zachary's appointment impact REGENXBIO?

Her legal and regulatory expertise may strengthen the company's governance and support its pipeline development.